27 lutego 2017Tessa pisze:

Proszę:

Serotonin neurotoxicity in rats after combined treatment with a dopaminergic agent followed by a nonneurotoxic 3,4-methylenedioxymethamphetamine (MDMA) analogue.

There is increasing evidence linking dopamine (DA) to the long-term serotonergic (5-HT) neurotoxic effects of certain substituted amphetamines such as 3,4-methylenedioxymethamphetamine (MDMA). The present study was undertaken to examine the importance of DA metabolism, uptake inhibition and release in the long-term effects of these drugs by combining various dopaminergic agents with an analogue of MDMA that had low neurotoxic liability, namely 5,6-methylenedioxy-2-aminoindan (MDAI). Monoamine and metabolite levels and the number of 5-HT uptake sites (using [3H]paroxetine binding) were determined 3 hours or 1 week after treatments. Combining the monoamine oxidase inhibitors, clorgyline (MAOA selective) or deprenyl (MAOB selective) with MDAI did not result in any long-term reductions of serotonergic markers. Similarly, combining the DA uptake inhibitor GBR-12909 with MDAI did not result in any long-term changes in monoamine levels at 1 week. In contrast, a single pretreatment of posttreatment with the nonvesicular DA releaser S-amphetamine and MDAI resulted in small but significant long-term changes in monoamine levels. More importantly, if a subacute dosing regimen (every 12 hours for 4 days) was utilized, the combination of S-amphetamine with MDAI resulted in a marked long-term decrease in the levels of cortical, hippocampal and striatal 5-HT, 5-HIAA and the number of 5-HT uptake sites. The results are discussed in terms of the significance of DA and especially nonvesicular DA release in the long-term effects of MDMA-like drugs.

https://www.ncbi.nlm.nih.gov/pubmed/1726189

Dyskusja na ten temat:
https://drugs-forum.com/threads/possibl ... ed.171150/

Combined administration of a non-neurotoxic 3,4-methylenedioxymethamphetamine analogue with amphetamine produces serotonin neurotoxicity in rats:
https://www.ncbi.nlm.nih.gov/pubmed/1717873

Recent research has discovered that dopamine’s main role in promoting MDMA neurotoxicity is by increasing body temperature: significant overheating is a very important factor in whether or not MDMA neurotoxicity will occur.

Don’t mix MDMA with other stimulants, such as amphetamines (speed/meth.) Combining other stimulant drugs with MDMA is a bad idea; the combination increases the risk of becoming seriously overheated, which we know is a major risk factor for neurotoxicity (and death and liver damage and many other bad things.)

https://dancesafe.org/drug-information/ ... eurotoxic/



Była jeszcze jedna dyskusja na ten temat na jednym z anglojęzycznych forów, jednak nie mogę jej znaleźć. Jak kiedyś na nią trafię to zedytuję posta.